.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Chinese Patent Office
US Department of Justice
Medtronic
Teva
Federal Trade Commission
McKesson
Daiichi Sankyo
Cerilliant

Generated: November 20, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020563

« Back to Dashboard
NDA 020563 describes HUMALOG PEN, which is a drug marketed by Lilly and is included in one NDA. It is available from three suppliers. Additional details are available on the HUMALOG PEN profile page.

The generic ingredient in HUMALOG PEN is insulin lispro recombinant. There are thirty-eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the insulin lispro recombinant profile page.

Summary for 020563

Tradename:
3
Applicant:
1
Ingredient:
1
Patents:1

Pharmacology for NDA: 020563

Ingredient-typeInsulin

Medical Subject Heading (MeSH) Categories for 020563

Suppliers and Packaging for NDA: 020563

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
HUMALOG
insulin lispro recombinant
INJECTABLE;INJECTION 020563 NDA Eli Lilly and Company 0002-7510 0002-7510-01 1 VIAL in 1 CARTON (0002-7510-01) > 10 mL in 1 VIAL
HUMALOG
insulin lispro recombinant
INJECTABLE;INJECTION 020563 NDA Eli Lilly and Company 0002-7510 0002-7510-17 1 VIAL in 1 CARTON (0002-7510-17) > 3 mL in 1 VIAL

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength100 UNITS/ML
Approval Date:Jun 14, 1996TE:RLD:Yes

Summary for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrength100 UNITS/ML
Approval Date:Aug 6, 1998TE:RLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength100 UNITS/ML
Approval Date:Sep 6, 2007TE:RLD:Yes
Patent:► SubscribePatent Expiration:Aug 9, 2024Product Flag?YSubstance Flag?Delist Request?

Expired Orange Book Patents for NDA: 020563

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly
HUMALOG
insulin lispro recombinant
INJECTABLE;INJECTION020563-001Jun 14, 1996► Subscribe► Subscribe
Lilly
HUMALOG KWIKPEN
insulin lispro recombinant
INJECTABLE;INJECTION020563-003Sep 6, 2007► Subscribe► Subscribe
Lilly
HUMALOG PEN
insulin lispro recombinant
INJECTABLE;INJECTION020563-002Aug 6, 1998► Subscribe► Subscribe
Lilly
HUMALOG PEN
insulin lispro recombinant
INJECTABLE;INJECTION020563-002Aug 6, 1998► Subscribe► Subscribe
Lilly
HUMALOG KWIKPEN
insulin lispro recombinant
INJECTABLE;INJECTION020563-003Sep 6, 2007► Subscribe► Subscribe
Lilly
HUMALOG
insulin lispro recombinant
INJECTABLE;INJECTION020563-001Jun 14, 1996► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Covington
Merck
UBS
Fish and Richardson
Colorcon
Chubb
Citi
Cipla
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot